Like HER2 amplification and KRAS mutations, rare MET-amplified cells were found in pretreatment tumor material from one out of three patients with MET-driven acquired resistance, suggesting that preexisting clones were selected under the pressure of anti-EGFR therapy. The gene discussed is KRAS; the disease is neoplasm.